66th ASH Annual Meeting: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS

Symposia: Myelodysplastic Syndromes: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Acute Myeloid Malignancies, AML, MDS, Research, Clinical trials, Adult, MPN, Clinical Research, Chronic Myeloid Malignancies, CMML, Diseases, Therapy sequence, Treatment Considerations, Adverse Events, Myeloid Malignancies, Study Population, Human

Ballroom 20AB (San Diego Convention Center)

Moderators:

Moaath K. Mustafa Ali, MD, MPH, Cleveland Clinic Taussig Cancer Institute and Anoop K Enjeti, MBBS, FRCPA, MD, MRCP, Calvary Mater Hospital

Disclosures:

No relevant conflicts of interest to declare.

4:00 PM

349

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Sophie Park, MD, PhD¹, Bohrane Slama²^*, Marius Moldovan³^*, David Rombaut⁴^*, Marie Templé⁵^*, Aspasia Stamatoullas, MD⁶^*, Maud D'Aveni, MD, PhD⁷^*, Stephane Cheze, MD⁸^*, Sylvain Thepot, MD⁹^*, Jose Miguel Torregrosa Diaz, MD¹⁰^*, Sophie Dimicoli¹¹^*, Mathieu Meunier¹²^*, Kamel Laribi¹³^*, Reza Tabrizi¹⁴^*, Anne Banos, MD¹⁵^*, Alice Garnier, MD¹⁶^*, Celia Salanoubat¹⁷^*, Adrien Contejean¹⁸^*, Mael Heiblig, MD, PhD¹⁹^*, Laurent Pascal, MD, PhD²⁰, Clemence Santana²¹^*, Ali Arar²²^*, Ramdane Tekrane²³^*, Fatiha Chermat²⁴^*, Olivier Kosmider, PharmD, PhD²⁵^*, Michaela Fontenay, MD, PhD²⁶^* and Pierre Fenaux, MD²⁷

¹Hematology Department, CHU Grenoble, Grenoble Cedex 9, France
²Service d'onco-hématologie, Centre Hospitalier Général d'Avignon, Avignon, FRA
³CH Perigueux, Perigueux, FRA
⁴Laboratory of Hematology, Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104; Assistance Publique-Hôpitaux de Paris Centre, Hôpital Cochin, Paris, FRA
⁵Hematology Laboratory, Hôpital COCHIN, Paris, FRA
⁶Department of Hematology, Centre Henri Becquerel, Rouen, France, Rouen, FRA
⁷Department of Haematology,, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, Vandoeuvre-les-Nancy, France
⁸Institut d'Hématologie de Basse-Normandie, Centre Hospitalier de Caen Normandie, Caen, France
⁹Department of Clinical Hematology, Angers University Hospital, ANGERS, NA, France
¹⁰CHU de Poitiers, University Hospital of Poitiers, Poitiers, France
¹¹Department of Hematology, Bordeaux University Hospital, Pessac, FRA
¹²Department of Hematology CHU Grenoble Alpes, Grenoble, France
¹³Hématologie Clinique, CH Le Mans, Le Mans, France
¹⁴CH Mont de Marsan, Mont De Marsan, FRA
¹⁵Centre Hospitalier De Bayonne, Bayonne, FRA
¹⁶CHU Nantes Hôpital Hôtel Dieu Hématologie Clinique, Nantes, France
¹⁷Department of Hemaatology, Sud Francilien Hospital, Corbeil-Essonnes, FRA
¹⁸Département d'Hématologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France
¹⁹Hematology Department, CHU de Lyon, Pierre-Bénite, France
²⁰Department of Hematology, Hôpital Saint Vincent-De-Paul, Lille, France
²¹Département d'hématologie, Centre Leon Berard, CH de Valence, Lyon Valence, France
²²Oncologie Medicale Hematologie Clinique, Orleans University Hospital, Orleans, FRA
²³Groupe Francophone des Myelodysplasies, Paris, France
²⁴Groupe Francophone des Myelodysplasies, Hôpital St Louis/université de Paris Cité, Paris, FRA
²⁵Laboratory of Hematology, Université Paris Cité and Assistance Publique-Hôpitaux de Paris. Centre, Hôpital Cochin, Paris, France
²⁶Laboratory of Hematology, Université Paris Cité and Assistance Publique-Hôpitaux de Paris Centre, Hôpital Cochin, Groupe Francophone des Myelodysplasies, Paris, France
²⁷Service Hématologie Seniors, Assistance Publique des Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France

4:15 PM

350

Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial

Guillermo Garcia-Manero, MD¹, Valeria Santini²^*, Amer M. Zeidan, MBBS, MHS³, Rami S. Komrokji, MD⁴, Veronika Pozharskaya⁵^*, Karen L. Keeperman⁵^*, Yinzhi Lai⁵^*, Barkha Aggarwal⁵^*, Dimana Miteva⁶^*, David Valcárcel Ferreiras⁷^*, Pierre Fenaux, MD⁸, Jake Shortt⁹^*, Matteo Giovanni Della Porta, MD¹⁰^* and Uwe Platzbecker, MD¹¹

¹MD Anderson Cancer Center, Houston, TX
²University of Florence Medical School, Florence, Italy
³Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT
⁴Moffitt Cancer Center, Tampa, FL
⁵Bristol Myers Squibb, Princeton, NJ
⁶Bristol-Myers Squibb, Princeton, NJ
⁷Hospital Vall d'Hebron, Barcelona, Spain
⁸Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
⁹Monash University, Clayton, AUS
¹⁰Humanitas University, Milan, Italy
¹¹University Hospital Leipzig, Leipzig, Germany

4:30 PM

351

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Lionel Ades, MD, PhD¹, Thomas Cluzeau, MD, PhD², Thibault Comont³^*, Lorea Aguinaga, MD⁴^*, Aspasia Stamatoullas, MD⁵^*, Mathieu Meunier⁶^*, Emmanuel Gyan, MD, PhD⁷, Alice Garnier, MD⁸^*, Maud D'Aveni, MD, PhD⁹^*, Sylvain Thépot, MD¹⁰^*, Marie Sebert, MD, PhD¹¹^*, Marius Moldovan¹²^*, Anouk Walter Petrich, MD¹³^*, Karine Lemarie¹⁴^*, Fatiha Chermat¹⁵^*, Michaela Fontenay¹⁶^*, Sylvie Chevret¹⁷^* and Pierre Fenaux, MD¹⁸

¹Hopital Saint Louis, Paris, France
²Department for Clinical Hematology, Nice University Hospital, Nice, Provence Alpes Cote d'Azur, France
³Internal Medicine and Immune Diseases, University Hospital Toulouse - Cancer Institute, Toulouse, France
⁴Service Hématologie Seniors, Assistance Publique des Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France, Paris, France
⁵Department of Hematology, Centre Henri Becquerel, Rouen, France, Rouen, FRA
⁶Department of Hematology CHU Grenoble Alpes, Grenoble, France
⁷Service D'Hematologie Et Therapie Cellulaire, Tours Cedex, France
⁸CHU Nantes Hôpital Hôtel Dieu Hématologie Clinique, Nantes, France
⁹Department of Haematology,, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, Vandoeuvre-les-Nancy, France
¹⁰Centre Hospitalier Universitaire d'Angers, Angers, France
¹¹Hematology department, Saint-Louis Hospital, Paris, France
¹²CH Perigueux, Perigueux, FRA
¹³Biostatistics and Medical Information Department, Saint Louis University Hospital, AP-HP, Université Paris Cité, Paris, France
¹⁴Groupe Francophone des myelodysplasies, Paris, FRA
¹⁵Groupe Francophone des Myelodysplasies, Hôpital St Louis/université de Paris Cité, Paris, FRA
¹⁶Laboratory of Hematology, Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104; Assistance Publique-Hôpitaux de Paris Centre, Hôpital Cochin, Paris, FRA
¹⁷Biostatistics and Medical Information Department, Saint Louis Hospital, Assistance Publique — Hôpitaux de Paris (AP-HP), Paris, France
¹⁸Service Hématologie Seniors, Assistance Publique des Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France

4:45 PM

352

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Uwe Platzbecker, MD¹, Valeria Santini²^*, Amer M. Zeidan, MBBS, MHS³, Mikkael A. Sekeres, MD⁴, Pierre Fenaux, MD⁵, Azra Raza, MD⁶, Moshe Mittelman, MD⁷, Sylvain Thépot, MD⁸^*, Rena Buckstein, MD, FRCPC⁹, Ulrich Germing, MD¹⁰^*, Yazan F Madanat, MD¹¹, Maria Diez-Campelo, MD, PhD¹²^*, David Valcarcel, MD, PhD¹³, Anna Jonasova, MD, PhD¹⁴^*, Souria Dougherty, MBA¹⁵^*, Sheetal Shah, BA¹⁵^*, Qi Xia, PhD¹⁵^*, Libo Sun, PhD¹⁵^*, Shyamala Navada, MD¹⁶^*, Michael R. Savona, MD¹⁷ and Rami S. Komrokji, MD¹⁸

¹Leipzig University Hospital, Leipzig, Germany
²MDS Unit, Hematology, University of Florence, DMSC, AOUC, Florence, Italy
³Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, New Haven, CT
⁴Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁵Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
⁶Columbia University Medical Center, New York, NY
⁷Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel
⁸Centre Hospitalier Universitaire d'Angers, Angers, France
⁹Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
¹⁰Department of Hematology, Oncology and Clinical Immunology, University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany
¹¹Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
¹²Hospital Clínico Universitario de Salamanca, Salamanca, Spain
¹³Hospital Universitari Vall d'Hebron, Barcelona, Spain
¹⁴1st Medical Department – Hematology, General Hospital, Prague, Czech Republic
¹⁵Geron Corporation, Foster City, CA
¹⁶Executive Medical Director, Geron, Foster City, CA
¹⁷Vanderbilt University Medical Center, Nashville, TN
¹⁸Moffitt Cancer Center, Tampa, FL

5:00 PM

353

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Guillermo Garcia-Manero, MD¹, Yasmin Abaza, MD², Peter L. Greenberg, MD³, Tamanna Haque, MD⁴^*, Kyra Velázquez Kennedy, MD⁵^*, Matteo Giovanni Della Porta, MD⁶^*, Melissa G Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD⁷^*, Maximilian Stahl, MD⁸, Zhuoer Xie, MD, MS⁹, Abhishek A. Mangaonkar, MBBS¹⁰, Pinkal Desai¹¹, Amy E. DeZern, MD, MHS¹², Alice Garnier, MD¹³^*, Mathieu Meunier¹⁴^*, Anna Maria Pelizzari, MD¹⁵^*, Uwe Platzbecker, MD¹⁶, Katja Sockel, MD¹⁷^*, Ashwin Kishtagari, MBBS¹⁸, Hongbo Lu¹⁹^*, Luca Manganelli²⁰^*, Lexiang Ji¹⁹^*, Zheng Yan¹⁹^*, Yutong Li²¹^*, Mike Roy²²^*, Ewa Gatlik²³^*, Arti Singh²¹^*, Valerie Beaulieu¹⁹^*, Marc Pelletier¹⁹^*, Philipp Rauch²³^* and Harinder Gill, MBBS, MD, FRCP (Edin, Glasg, Lond), FRCPath, FHKCP, FHKAM (Medicine)²⁴

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Northwestern University, Chicago, IL
³Stanford Cancer Center, Stanford, CA
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Hospital Ramon Y Cajal Departamento de Hematologia, Madrid, Spain
⁶IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
⁷National University Cancer Institute Singapore, National University Health System, Singapore, Singapore
⁸Dana Farber Cancer Institute, Boston, MA
⁹Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁰Mayo Clinic, Rochester, MN
¹¹Weill Cornell Medicine New York Presbyterian Hospital, New York, NY
¹²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
¹³CHU Nantes Hôpital Hôtel Dieu Hématologie Clinique, Nantes, France
¹⁴Department of Hematology CHU Grenoble Alpes, Grenoble, France
¹⁵ASST Spedali Civili Di, Brescia, Italy
¹⁶Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
¹⁷Medical Clinic I, University Hospital Dresden, TU Dresden, Germany
¹⁸Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Franklin, TN
¹⁹BioMedical Research, Novartis, Cambridge, MA
²⁰BioMedical Research, Novartis,, Basel, Switzerland
²¹BioMedical Research, Novartis, East Hanover, NJ
²²Novartis Pharmaceuticals Corporation, East Hanover, NJ
²³BioMedical Research, Novartis, Basel, Switzerland
²⁴School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong

5:15 PM

354

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Zhuoer Xie, MD, MS¹, Zena Komrokji²^*, Michael Otterstatter, PhD³^*, Ling Zhang, MD⁴, Lynn C. Moscinski, MD⁵, Najla H. Al Ali, Ms⁶^*, David Sallman, MD⁷, Jeffrey E Lancet, MD⁶, Amy E. DeZern, MD, MHS⁸, Mikkael A. Sekeres, MD⁹, Rami S. Komrokji, MD⁶, Nancy Gillis, PhD¹⁰ and Eric Padron, MD⁶

¹Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
³The Emmes Company, LLC, Rockville, MD
⁴Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer and Research Institute, Tampa, FL
⁵Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁷Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
⁸Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
⁹Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
¹⁰Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

637.O2.3 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS